Anti-TNF and postoperative complications in abdominal crohn's disease surgery

Bibliographic Details
Main Author: Yamamoto, Takayuki
Publication Date: 2019
Other Authors: Teixeira, Fabio Vieira, Saad-Hossne, Rogerio [UNESP], Kotze, Paulo Gustavo, Danese, Silvio
Format: Other
Language: eng
Source: Repositório Institucional da UNESP
Download full: http://dx.doi.org/10.2174/1389450120666190404144048
http://hdl.handle.net/11449/201197
Summary: Background: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted.
id UNSP_1283e31cfb69b37a97cb04d9c9c58cb9
oai_identifier_str oai:repositorio.unesp.br:11449/201197
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Anti-TNF and postoperative complications in abdominal crohn's disease surgeryAnastomotic complicationsAnti-TNF agentsAnti-tumour necrosis factor-alpha agentsBiologicsCrohn’s diseaseInfectious complicationsPostoperative complicationsSurgeryBackground: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted.Department of Surgery and IBD Centre Yokkaichi Hazu Medical CentreDepartment of Colorectal Surgery Gastrosaude ClinicDigestive Surgery Department São Paulo State University (UNESP)Colorectal Surgery Unit Catholic University of Paraná (PUCPR)IBD Centre Department of Gastroenterology Humanitas Clinical and Research CentreDigestive Surgery Department São Paulo State University (UNESP)Yokkaichi Hazu Medical CentreGastrosaude ClinicUniversidade Estadual Paulista (Unesp)Catholic University of Paraná (PUCPR)Humanitas Clinical and Research CentreYamamoto, TakayukiTeixeira, Fabio VieiraSaad-Hossne, Rogerio [UNESP]Kotze, Paulo GustavoDanese, Silvio2020-12-12T02:26:32Z2020-12-12T02:26:32Z2019-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other1339-1348http://dx.doi.org/10.2174/1389450120666190404144048Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019.1873-55921389-4501http://hdl.handle.net/11449/20119710.2174/13894501206661904041440482-s2.0-85072686975Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengCurrent Drug Targetsinfo:eu-repo/semantics/openAccess2024-08-14T14:19:56Zoai:repositorio.unesp.br:11449/201197Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-08-14T14:19:56Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Anti-TNF and postoperative complications in abdominal crohn's disease surgery
title Anti-TNF and postoperative complications in abdominal crohn's disease surgery
spellingShingle Anti-TNF and postoperative complications in abdominal crohn's disease surgery
Yamamoto, Takayuki
Anastomotic complications
Anti-TNF agents
Anti-tumour necrosis factor-alpha agents
Biologics
Crohn’s disease
Infectious complications
Postoperative complications
Surgery
title_short Anti-TNF and postoperative complications in abdominal crohn's disease surgery
title_full Anti-TNF and postoperative complications in abdominal crohn's disease surgery
title_fullStr Anti-TNF and postoperative complications in abdominal crohn's disease surgery
title_full_unstemmed Anti-TNF and postoperative complications in abdominal crohn's disease surgery
title_sort Anti-TNF and postoperative complications in abdominal crohn's disease surgery
author Yamamoto, Takayuki
author_facet Yamamoto, Takayuki
Teixeira, Fabio Vieira
Saad-Hossne, Rogerio [UNESP]
Kotze, Paulo Gustavo
Danese, Silvio
author_role author
author2 Teixeira, Fabio Vieira
Saad-Hossne, Rogerio [UNESP]
Kotze, Paulo Gustavo
Danese, Silvio
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Yokkaichi Hazu Medical Centre
Gastrosaude Clinic
Universidade Estadual Paulista (Unesp)
Catholic University of Paraná (PUCPR)
Humanitas Clinical and Research Centre
dc.contributor.author.fl_str_mv Yamamoto, Takayuki
Teixeira, Fabio Vieira
Saad-Hossne, Rogerio [UNESP]
Kotze, Paulo Gustavo
Danese, Silvio
dc.subject.por.fl_str_mv Anastomotic complications
Anti-TNF agents
Anti-tumour necrosis factor-alpha agents
Biologics
Crohn’s disease
Infectious complications
Postoperative complications
Surgery
topic Anastomotic complications
Anti-TNF agents
Anti-tumour necrosis factor-alpha agents
Biologics
Crohn’s disease
Infectious complications
Postoperative complications
Surgery
description Background: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
2020-12-12T02:26:32Z
2020-12-12T02:26:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.2174/1389450120666190404144048
Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019.
1873-5592
1389-4501
http://hdl.handle.net/11449/201197
10.2174/1389450120666190404144048
2-s2.0-85072686975
url http://dx.doi.org/10.2174/1389450120666190404144048
http://hdl.handle.net/11449/201197
identifier_str_mv Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019.
1873-5592
1389-4501
10.2174/1389450120666190404144048
2-s2.0-85072686975
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Current Drug Targets
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1339-1348
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1834483699621560320